

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A composition for the nasal administration of an antihistamine in a dry powder form suitable for administration of a drug said antihistamine to the nasal region, the dry powder form comprising:

microparticles comprising the antihistamine and a diketopiperazine wherein said microparticles are sized such that the particles are preferentially retained in the nasal cavity and have a particle size of between about 10 microns and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns, and wherein the composition does not pass into the pulmonary system.

2. (Cancelled)

3. (Previously Presented) The composition of claim 1 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

4. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

5. (Previously Presented) The composition of claim 1 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

6. (Cancelled)

7. (Previously Presented) A drug delivery device for nasal administration comprising

an antihistamine in a dry powder form in a dosage formulation for administration to the nasal region and,

a device for delivering a measured dose of the antihistamine to the nasal mucosa,

wherein the dry powder form comprises microparticles comprising the antihistamine and a diketopiperazine and said microparticles have a particle size of between about 10 microns and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns, and wherein the composition does not pass into the pulmonary system.

8. (Original) The device of claim 7 wherein the device is a nasal insufflator.

9. (Cancelled)

10. (Original) The device of claim 7 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

11. (Previously Presented) The device of claim 7 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

12. (Currently Amended) The device of claim 7 wherein the diketopiperazine diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

13. (Cancelled)

14. (Previously Presented) A method of administering an antihistamine to the nasal region of a patient in need thereof, comprising:

nasally administering a dry powder suitable for nasal administration, wherein the dry powder form comprises microparticles comprising the antihistamine and a diketopiperazine and said microparticles have a particle size of between about 10 microns and about 20 microns in diameter and wherein more than 50% of the microparticles have a particle size greater than about 10 microns; and

wherein the composition does not pass into the pulmonary system.

15. (Cancelled)

16. (Original) The method of claim 14 wherein the antihistamine is selected from the group consisting of chlorpheniramine and azelastine.

17. (Previously Presented) The method of claim 14 wherein the diketopiperazine is a substitution derivative selected from the group consisting of diketomorpholines, diketooxetanes and diketodioxanes.

18. (Previously Presented) The method of claim 14 wherein the diketopiperazine is formed by cyclodimerization of amino acid ester derivatives.

19. (Cancelled)

20. (Previously Presented) The composition of claim 1 wherein said microparticles are formed by spray drying.

21. (Previously Presented) The device of claim 7 wherein the microparticles are formed by spray drying.